Here's the straightforward solution: VIP is just not a normal-purpose anti-inflammatory peptide you'll be able to substitute into any protocol expecting wide immune suppression. Its effects are receptor-precise, tissue-dependent, and timing-delicate in ways that make protocol design and style drasti